Biolegend, 584006, Biotinylated Recombinant Human TIGIT-Fc Chimera (carrier-free), 100μg

TIGIT (T-cell immunoreceptor with Ig and ITIM domains precursor), containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif. TIGIT is an inhibitory receptor expressed on the surface of natural killer (NK) cells. TIGIT recognizes nectin and nectin-like adhesion molecules and thus plays a critical role in the innate immune response to malignant transformation. TIGIT in conjunction CD226 forms a pathway that has prominent similarities to the costimulatory CD28/CTLA-4 pathway. CD226 and TIGIT bind the same set of ligands (CD155 and CD112) and CD226 is a positive regulator of T cell responses, while TIGIT inhibits them. Knockdown of TIGIT expression  in human CD4 + T cells results in an increase of both T-bet and IFNγ mRNA and protein expression. These effects are overcome by blocking CD226 signaling indicating that TIGIT exerts immunosuppressive effects by competing with CD226 for the same ligand CD155. The binding of CD115 to TIGIT on human dendritic cells enhanced the production of interleukin 10 and diminished the production of interleukin 12p40. TIGIT shows inhibitory effect in cell-signaling pathway in murine models of experimental autoimmune encephalomyelitis (EAE). Loss of TIGIT expression in mice results in hyperproliferative T cell responses and increased susceptibility to EAE.
100μg
Source: Human TIGIT, amino acid (Met 22 - Pro 141) (Accession: # Q495A1-1), with a C-terminal human IgG1 (Pro100-Lys330), and an Avi-tag, was expressed in 293E cells. Human TIGIT-Avi tag was site-specifically biotinylated by enzyme BirA.
Molecular Mass: The 380 amino acid recombinant protein has a predicted molecular mass of approximately 43.9 kD. The DTT-reduced and non-reduced proteins migrate at approximately 45 - 55 kD and 85 - 115 kD, respectively by SDS-PAGE. The predicted N-terminal amino acid is Met.
Purity: > 95%, as determined by Coomassie stained SDS-PAGE.
Formulation: 0.22 µm filtered protein solution is in PBS, pH 7.2
Endotoxin Level: Less than 0.1 EU per µg cytokine as determined by the LAL method.
Concentration: 25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin the vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity: Biotinylated recombinant human TIGIT-Fc chimera binds to immobilized recombinant human CD155-Fc chimera in a dose-dependent manner. The ED50 for this effect is 7.5 – 45 ng/mL.
Application: Bioassay
Application Notes: BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected].
Structure: Homodimer
Distribution: Human follicular B helper T cells (TFH), regulatory, memory and activated T cells, NK cells
Function: Immunosuppressive effects by binding CD115 and modulating cytokine production by DC. Inhibits NK cell cytotoxicity. Inhibits T cell functions by competing with CD226. Tregs TIGIT+ cells suppress proinflammatory Th1 and Th17 cell, but not Th2 cell responses.
Interaction: Dendritic cells, monocytes
Ligand/Receptor: Poliovirus receptor (PVR/CD155) and nectin-2 (PRR-2/CD112)
Bioactivity: Biotinylated recombinant human TIGIT-Fc chimera binds to immobilized recombinant human CD155-Fc chimera.
Biology Area: Immunology, Inhibitory Molecules
Molecular Family: Adhesion Molecules, Immune Checkpoint Receptors, Soluble Receptors
Antigen References: Yu X, et al. 2009. Nat Immunol. 10:48-57. Stanietsky N, et al. 2009. Proc Natl Acad Sci USA. 106:17858. Joller N, et al. 2011. J Immunol. 186:1338-42. Tahara-Hanaoka S, et al. 2004. Int Immunol. 16:533-8. Lozano E, et al. 2012. J Immunol. 188:3869-75. Joller N, et al. 2014. Immunity. 40:569-81. Deuss FA, et al. 2017. J Biol Chem. 292:11413-11422.
Gene ID: 201633
UniProt: View information about TIGIT on UniProt.org
Regulatory Status: RUO
Other Names: T-Cell Immunoreceptor with Ig and ITIM domains, T cell Ig and ITIMdomain (TIGIT), V-Set and Immunoglobulin Domain-ContainingProtein 9 (VSIG9), V-Set and Transmembrane Domain-ContainingProtein 3 (VSTM3), WUCAM